subject: Aarkstore Enterprise Acacia Pharma Ltd - Product Pipeline Review - Q4 2010 [print this page] Aarkstore announce a new report "Acacia Pharma Ltd. - Product Pipeline Review - Q4 2010 " through its vast collection of market research report.
Acacia Pharma Ltd.- Product Pipeline Review - Q4 2010 provides data on the companys research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Directs proprietary databases, Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Directs team.
Scope
- Acacia Pharma Ltd.- brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Acacia Pharma Ltd.human therapeutic division.
- overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Acacia Pharma Ltd.with complete description of the products developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Aegerion Pharmaceuticals, Inc.s pipeline in the last quarter.
- key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Aegerion Pharmaceuticals, Inc.s strategic position with total access to detailed information on its Product pipeline.
- Assess the growth potential of Acacia Pharma Ltd.in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Aegerion Pharmaceuticals, Inc.s W471&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Aegerion Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
